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on Langerhans cells due to a rare
point mutation in the coding
sequenceTo the Editor:
The family of CD1 molecules is structurally similar to MHC
class I molecules, but the 2 protein families mediate fundamen-
tally different immune functions. MHC class I molecules present
peptides to T cells, whereas CD1 molecules present lipids to
natural killer T cells and other CD1-restricted T cells.1 CD1a is
highly expressed on human Langerhans cells (LCs), a specialized
mononuclear phagocyte that is prevalent in the epithelial cell layer
of the skin and mucosal surfaces. Epidermal LCs can function as
classical antigen-presenting cells (APCs) to induce naive T-cell
responses in draining lymph nodes, but also have a regulatory
function in the skin via local induction of regulatory T cells and
maintenance of epithelial barrier integrity.2,3 Human dermal den-
dritic cells (DCs) also express CD1a, but in much lower amounts
compared with LCs. CD1a1 dermal DCs, which coexpress CD1c,
have been shown to efficiently stimulate CD41 and CD81 T cells
in vitro.4,5 However, immune deficiencies due to selective CD1a
defects have not been previously described, and it has proved diffi-
cult to dissect the specific role of CD1a in immune regulation.
During the course of a clinical study that involvedanalysis ofAPC
subsets in human skin biopsies by flow cytometry, we identified a
healthy Vietnamese individual, donor 007, who showed complete
absence of CD1a expression on skinAPCs (Fig 1,A). This case pre-
sented an opportunity to study the biological significance of CD1a
expression. To check whether LCs were absent altogether in donor
007, we obtained a second skin biopsy, separated the epidermis
from the underlying structures, and stained the epidermal tissues
with antibodies binding to CD1a and to HLA-DR. Donor 007 LCs
displayed intense HLA-DR staining with typical dendritic
morphology, but CD1a staining was minimal (Fig 1, B).
We next addressed whether the CD1a deficiency represented a
generic expression defect, using monocyte-derived dendritic cells
(moDCs) as a model. In keeping with our earlier observations,
moDCs from donor 007 showed no surface CD1a expression by
flow cytometry or immunohistochemistry (see Fig E1, A, in this
article’s Online Repository at www.jacionline.org), in contrast
to moDCs derived from a normal healthy control donor. Staining
with other anti-human CD1a clones, OKT6 and NA1/34-HLK,
showed the same result as staining with clone HI149 (see
Figs E2 and E3 in this article’s Online Repository at www.
jacionline.org). In addition, no costain with early endosome
antigen-1 and CD1awas observed, excluding CD1a accumulation
in early endosomes in donor 007 (Fig E1, B).
To address whether the CD1a defect was caused by a mutation
in the CD1a gene, we invited the parents and all 4 siblings of 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).donor 007 for a clinical assessment and CD1a expression
analysis. Summary clinical information for the family members
is presented in Table E1 in this article’s Online Repository at
www.jacionline.org. Apart from donor 007’s father, who had se-
vere Parkinson’s disease, the family members were generally
healthy and displayed apparently normal skin barrier function
and wound healing.
Both parents (001 and 002) and siblings 003, 004, and 006
showed normal CD1a surface expression on skin DCs and/or
moDCs by immunohistochemistry and flow cytometry (Fig E4,A,
in this article’s Online Repository at www.jacionline.org). How-
ever, skin DCs of sibling 005 showed complete absence of surface
CD1a expression, similar to donor 007 (Fig E4, B). Blood DC
subsets from familymembers, and fromSingaporean healthy con-
trols, were also analyzed by flow cytometry; the absence of CD1a
had no impact on the development of blood DC subsets, and did
not affect the expression of CD1c and CD1dmolecules, excluding
an intracellular CD1 protein trafficking defect (Fig E4, C-F).
To establish the genetic cause of the CD1a deficiency, we
isolated RNA frommoDCs for CD1a mRNA length and sequence
analysis (see Fig E5,A, in this article’s Online Repository at www.
jacionline.org). The lengths of the CD1a open reading frame from
donor 007, from the parents, and from 1 sibling were identical,
ruling out a shorter splice variant as the cause of the CD1a expres-
sion defect in donor 007. However, sequencing of the mRNA
identified a single nucleotide polymorphism (SNP)
(rs761269454) (Fig E5, B) that differed between donor 007 and
nonaffected familymembers. The rs761269454 T to C conversion
results in an amino acid change from Leucine to Proline at posi-
tion 285 of the CD1a protein, located in the a3 domain of CD1a
(Fig 2, A). Interestingly, parent 001 exhibited a double peak at this
nucleotide position, suggesting that both the normal and mutant
allele were expressed at the mRNA level, resulting in a normal
CD1a phenotype at the protein level (Fig E5, B, and Fig E4, A).
We next isolated whole blood genomic DNA from all family
members and sequenced the CD1a gene and 5000bases upstream
and downstream using Illumina MiSeq (see Fig E5, C [Sanger
sequencing] and Table E2 [MiSeq] in this article’s Online Repos-
itory at www.jacionline.org). Donors 007 and 005 were heterozy-
gous for rs761269454 (Fig E5, C, and Table E2), but expressed
only the variant form of CD1a (Fig E5, B), in contrast to parent
001 and sibling 006, who were also heterozygous but expressed
both alleles or at least the normal allele, respectively (Fig E4
and Fig E5, B). Intriguingly, we identified a second SNP
rs538916791 that introduces a stop codon at amino acid 94 of
the CD1a protein. The hereditary distribution of this SNP could
explain the CD1a expression pattern: in the presence of the
L285P SNP on one allele, the other allelewas expressed normally.
However, if one allele contained the L285P SNP and the other
allele contained the stop codon SNP, as for 005 and 007, only
the mutant L285P form could be expressed.
To test whether the L285P mutation was sufficient to abrogate
surface CD1a expression, we recombinantly expressed both the
reference/wild-type and the mutant forms of CD1a in human
embryonic kidney cells (a fibroblast cell line) and K562 cells (a
granulocytic/monocytic cell line) (Fig 2, B). We chose 2 cell lines
to address potential cell-type–specific differences in expression.
Flow cytometry analysis showed that only the reference but not
the mutant form of CD1a was expressed on the cell surface (Fig
2, B), whereas both forms were transcribed equally (Fig E3).
Immunohistochemistry of transfected HEK cells confirmed this
FIG 1. CD1a deficiency on skin DCs of a healthy adult.A, Single cells were isolated from skin biopsies from a
healthy individual and donor 007 and skin APCs were analyzed by flow cytometry. B, Epidermal sheets from
a control donor and from donor 007 were stained for HLA-DR (red) and CD1a expression (green). Hoechst
(blue) was used to stain cell nuclei, and samples were analyzed by confocal microscopy. Control data are
representative of more than 20 healthy donors. AF, Autofluorescence; DAP I, 49-6-diamidino-2-
phenylindole, dihydrochloride; FSC-W, forward scatter-width; SSC, side scatter.
J ALLERGY CLIN IMMUNOL
DECEMBER 2016
1710 LETTERS TO THE EDITORfinding (Fig 2,C). Different transfection ratios of normal tomutant
CD1a resulted in the expected expression level of normal CD1a
and excluded competition at the translational level (Fig 2, B).
In summary, we describe complete CD1a deficiency in 2
apparently healthy Vietnamese adults, and have identified a novel
mutation responsible for the expression defect. This did not result
in any apparent CD1a-related skin abnormalities, or in systemic
immune impairment in either individual.
CD1a-restricted T cells specific for the mycobacterial lip-
opeptide didehydroxymycobactin can be detected in the blood oftuberculin-positive individuals ex vivo. Besides a potential role of
CD1a-restricted T cells in antibacterial responses, presentation of
natural skin lipids to CD1a-autoreactive T cells has been sug-
gested to be essential for maintenance of the skin immune barrier.
According to this hypothesis, a skin injury causes CD1a-
expressing epidermal LCs to activate dermal CD1a-restricted
T cells, resulting in IL-22 secretion, which, in turn, helps to repair
any epithelial damage.6,7 Moreover, the inflammation caused by
bee andwasp venom ismediated via CD1a-restricted self-reactive
T cells in the skin. These venoms contain phospholipase A2,
FIG 2. Recombinant expression of the mutant CD1a-L285P reproduces the in vivo expression defect. A,
Structure of the CD1a molecule in complex with a sulfatide (Protein Data Bank 1ONQ). The a domains
(pink), b2 microglobulin (blue), and the position of L285P in the a3 subunit (green) are shown. B, CD1a sur-
face expression ofWT and L285P CD1a-transfected HEK and K562 cells analyzed by flow cytometry 24 hours
after transfection. Cells were transfected with the indicated ratios of WT and L285P CD1a plasmid. Bar
graphs show means 6 SEM of % CD1a-expressing cells measured in 2 independent experiments with total
n 5 4. C, CD1a expression on transfected HEK cells analyzed by immunofluorescence microscopy. HEK,
Human embryonic kidney; SSC-A, side scatter-area; WT, wild-type.
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on CD1a, resulting in the activation of CD1a-restricted T cells.8
None of the family members described here had a history of
tuberculosis, although all are likely to have been exposed because
tuberculosis is endemic in the region. Similarly, there was no
apparent difference in the occurrence of common skin infections,
or in wound healing, between family members displaying
different CD1a expression patterns, and no family members
recalled unusual reactions to bee or wasp stings.
These findings suggest that it is unlikely that CD1a surface
expression is an essential element in the proposed pathway bywhich LCs are thought to function to maintain the integrity of the
skin immune barrier.
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http://dx.doi.org/10.1016/j.jaci.2016.05.028Pre-existing anti-PEG antibodies
are associated with severe immedi-
ate allergic reactions to pegnivaco-
gin, a PEGylated aptamerTo the Editor:
PEGylation is commonly used to extend half-life and limit
volume of distribution of an increasing number of nucleic acid,TABLE I. Incidence of allergic reactions within 24 hours by treatmen
Type of allergic reaction
Bivalirudin
(n 5 1601
Any allergic reaction 10 (0.62)
Serious allergic reaction 1 (0.06)
Severe allergic reaction 4 (0.25)
Nonsevere allergic reaction 6 (0.37)
Anaphylaxis 1 (0.06)
Allergic reaction onset <1 h after study drug dosing 2 (0.12)
Severe allergic reaction onset <1 h after study drug dosing 1 (0.06)
Data presented as n (%). Bivalirudin was the reference group in the calculation of OR.
OR, Odds ratio.peptide, and small molecule therapeutics. Pegnivacogin is a
modified 31-nucleotide RNA aptamer that binds to and inhibits
factor IXa conjugated to an inert 40-kD branched methoxypoly-
ethylene glycol polymer. Although early clinical testing did not
identify any safety concerns, the phase IIb Randomized,
Partially Blinded, Multicenter, Active-Controlled, Dose-
Ranging Study Assessing the Safety, Efficacy, and Pharmaco-
dynamics of the REG1 Anticoagulation System in Patients with
Acute Coronary Syndromes (RADAR) trial was stopped after 3
allergic reactions.1 An extensive investigation demonstrated
elevated levels of IgG anti-PEG antibodies in the 3 patients
with allergic events, suggesting that the PEG moiety, and not
the oligonucleotide, was the causative allergic agent.2 On the
basis of previous safety record of PEGylated products, investi-
gators and regulatory authorities agreed that pegnivacogin
should undergo additional definitive testing incorporating a
risk mitigation and action plan in a phase III trial (Randomized,
Open-label, Multi-Center, Active-Controlled, Parallel Group
Study to Determine the Efficacy and Safety of the REG1 Anti-
coagulation System Compared to Bivalirudin in Patients Under-
going Percutaneous Coronary Intervention [REGULATE-PCI])
in which subjects undergoing percutaneous coronary
intervention were randomized to pegnivacogin or bivalirudin.3
Methodology of the trial, planned biochemical analyses, statis-
tical analyses, and allergy definitions are available in the first
and second sections in this article’s Online Repository at
www.jacionline.org. REGULATE-PCI was ultimately termi-
nated after enrollment of 3,232 of a planned 13,200 patients af-
ter an excess of allergic reactions in pegnivacogin-treated
patients.3
The incidence and timing of allergic reactions are summarized
in Table I. Descriptions of allergies meeting reporting criteria,
as judged by the investigators, are provided in the third
section in this article’s Online Repository at www.jacionline.
org. Assignment to pegnivacogin was associated with a
statistically significant increase in allergic reactions. Of the
clinical variables assessed, female sex, allergic reactions in the
past year, current smoking, and previous percutaneous coronary
intervention were associated with severe allergic reactions (see
Table E1 in this article’s Online Repository at www.jacionline.
org). There was no evidence of altered risk of allergic
reactions in patients premedicated with H1 or H2 blockers,
corticosteroids, beta blockers, or angiotensin-converting enzyme
inhibitors (see Table E2 in this article’s Online Repository at
www.jacionline.org).
As stipulated in the risk mitigation and action plan, measure-
ments of complement activation, tryptase release, and anti-PEG
IgG antibodies were performed in all patients experiencing
allergic reactions within 24 hours of pegnivacogin or bivalirudint arm
)
Pegnivacogin
(n 5 1605)
Total
(N 5 3206) OR (95% CI)
24 (1.5) 34 (1.06) 2.4 (1.2-5.1)
10 (0.62) 11 (0.34) 10.0 (1.3-78.5)
18 (1.12) 22 (0.69) 4.5 (1.5-13.4)
6 (0.37) 12 (0.37) 1.0 (0.3-3.1)
10 (0.62) 11 (0.34) 10.0 (1.3-78.5)
16 (1.0) 18 (0.56) 8.1 (1.9-35.1)
12 (0.74) 13 (0.40) 12.1 (1.6-92.8)
METHODS
Clinical methods
To study the index case and his family members, ethical approval was
obtained from the Ethical Committee of the Hospital for Tropical Diseases of
Ho Chi Minh City and the Oxford Tropical Research Ethics Committee.
Following written informed consent, a detailed clinical assessment was
performed by a single physician, and a blood sample was obtained for a full
hematology/biochemistry panel together with a sample for the immunological
studies described below. Four of 7 participants also consented to a shave skin
biopsy performed by the same physician.
Control samples consisted of anonymized blood specimens provided by
healthy donors to the National University Hospital of Singapore Blood Bank.
All donors gave written informed consent.
Skin biopsies
Shave biopsies were taken under local lignocaine anesthesia using
DermaBlades (Personna Medical, AccuTec Blades Inc, Verona, Va). Biopsies
were collected in RPMI medium and cut into 2 parts. One part was fixed
overnight at 48C in PBS containing 30% sucrose and 2% paraformaldehyde,
then washed in 30% sucrose for 2 hours, and kept in PBS at 48C until use. The
other section of the biopsy was cut into small pieces and digested overnight at
378C in RPMI medium containing 0.8 mg/mL collagenase (Type IV,
Worthington-Biochemical, Lakewood, NJ) and 100 U/mL DNase (Roche,
Ho Chi Minh City, Vietnam). Digested tissue was disrupted by manual
pipetting, and connective tissue and debris were removed by filtering the cells
through a 70-mm filter. Cells were labeled with the following antibodies:
HLA-DR-PE-Cy7 (clone L243), CD45-V500 (clone HI30), CD1a-APC
(clone HI149), and CD14-PE (clone M5E2) (all from Becton Dickinson,
BD Biosciences, San Jose, Calif) before flow cytometry analysis. The gating
strategy has been described elsewhere.E1
Differentiation of monocyte-derived DCs, histology,
and flow cytometry
PBMCs were isolated by Ficoll density gradient (GE Healthcare Life
Science, Singapore) and frozen in liquid nitrogen for later analysis.Monocytes
were isolated using CD14-microbead positive selection (STEMCELL Tech-
nologies Canada Inc, Singapore). CD141 monocytes were cultured in RPMI
medium supplemented with 10% FCS with 50 ng/mL recombinant human
GM-CSF and 10 ng/mL IL-4 (both from ImmunoTools, Friesoythe, Germany)
for 6 to 7 days to generate moDCs. Anti-CD1a clone HI149 (Biomarkers and
Immunoassays, Biolegend, San Diego, Calif) or clone OKT6E2 was used for
flow cytometry and histology.
For microscopy analysis, cells were seeded on Poly-L-Lysine–coated
chamber slides (Ibidi, Planegg/Martinsried, Germany) and fixedwith 4%para-
formaldehyde for 20minutes. Cells were then permeabilized with 0.1%Triton
X-100 and blocked with 3%BSA for 2 hours before the antibody was added at
room temperature and incubated for 2 hours. Hoechst (200 ng/mL; Invitrogen,
Thermo Fisher Scientific, Carlsbad, Calif) was added for 5 minutes and slides
were washed 3 times before addition of Prolong Gold (Life Technologies Cor-
poration, Thermo Fisher Scientific, Carlsbad, Calif). Images were taken on an
Olympus IX81 confocal microscope.
PBMC flow cytometry analysis
PBMCs were isolated using Ficoll (GE Healthcare) or cell preparation
tubes (Becton Dickinson) and frozen for later analysis. Thawed cells
were stained and analyzed using a FACS-LSRII (Becton Dickinson). For
the DC subset analysis, the negative fractions of the CD14-positive sort
(see moDC generation) were used. DC subsets were determined
following a previously described gating strategyE3 that involved using an-
tibodies binding to lineage (CD19 [clone HIB-19], CD20 [clone 2H7],
CD3 [clone UCHT1], CD56 [clone MEM188]), CD45 (clone HI30),
HLA-DR (clone L243), CD14 (clone RM052; Life Sciences and Diag-
nostics, Beckman Coulter, Brea, Calif), CD11c (clone B-ly6), CD1c
(clone L161), CD141 (clone AD5-14H12; MACS FlowCytometry, Milte-
nyi Biotec, Singapore), CD34 (clone 563; BD Pharmingen, BD Biosci-
ences, San Jose, Calif), CD123 (clone 7G3), and Hoechst. For the
analysis of B cells and the analysis of CD1d expression, PBMCs were
stained with CD45 (clone HI30), CD19 (clone HIB19; BD Pharmingen),
CD1c (clone L161), CD1d (clone 51.1), CD3 (clone UCHT1), CD14
(clone RM052; Beckman Coulter), and Hoechst. All antibodies were pur-
chased from Biolegend, unless otherwise stated.
Sequencing of messenger RNA and genomic DNA
For mRNA sequencing, moDCs were collected into catch buffer (10 mM
Tris, pH 8, RNase inhibitor RNasin [Promega Corporation, Madison, Wis])
and frozen at 2808C until use. cDNAwas generated and amplified using the
One-Step PCRKit (Qiagen, Hilden, Germany) with the following primers: 59-
CTA CTT CCATTG TTA GCT GTT CTC CC and 59-TGT CTTAAC AGA
AAC AGC GTT TCC T. The PCR product was loaded on an agarose gel and
the product was isolated with a gel extraction kit (Qiagen).
Genomic DNA was isolated from whole blood using the DNeasy Blood &
Tissue Kit (Qiagen). Sequencing of the CD1a gene was first performed using
overlapping primers and sequencing the PCR products with Sanger sequencing
(Fig E5, C).
For a deeper coverage,we used IlluminaMiSeq to sequence theCD1agene and
approximately 5-kb region upstream and downstream of the coding regions,
inclusive of the 59 and 39 UTRs. The entire 13.8-kb genomic sequences
(->hg38_refGene_NM_001763 range5chr1:158249137-158262944) were sub-
divided into 5 shorter regions and were amplified for library preparation. Primer
sequences and their positions can be found in the table below (Table E3).
Amplification was performed using 10 ng of total genomic DNA prepared
from blood as template using LongAmp Taq DNA polymerase (New England
Biolabs, Singapore) according to manufacturer’s instructions. PCR cycling
conditions for amplicon regions 1, 3, 4, and 5 were 948C for 30 seconds (initial
denaturation), followed by 25 cycles of 948C for 15 seconds (denaturation),
588C for 30 seconds (annealing), and 658C for 30 seconds (extension), with a
final elongation of 658C for 10 minutes. For amplifying the amplicon 2 region,
the cycling profile was similar to above except that the annealing was carried
out at a higher temperature (608C for 30 seconds). Amplified products were
purified using Agencourt Ampure XP beads (Beckman Coulter). Equimolar
amounts of PCR products were pooled together for each sample separately for
library preparation.
Libraries of pooled amplicons for each sample were prepared using the
Nextera XT kit (Illumina, San Diego, Calif) according to manufacturer’s
instructions. Libraries were constructed using 0.8 ng of pooled amplicons
as starting material. Briefly, fragmentation of template DNA (5 mL) was
carried out in 10 mL of Tagment DNA buffer using 5 mL of Amplicon
Tagment Mix. Indexes were added to Tagmented DNA using 12 PCR
cycles. The amplified and indexed libraries were purified and size selected
using Agencourt Ampure XP beads (Beckman Coulter). The length
distribution of the libraries was monitored using DNA 1000 kits on the
Agilent 2100 Bioanalyzer (Agilent Technologies, Singapore). Equimolar
amounts of purified libraries were pooled and sequenced using indexed PE
sequencing runs of 2 3 250bp on an Illumina MiSeq Personal Sequencer
(MiSeq Control Software Version 2.4.1.3). Each individual sample was
sequenced at an average depth of 2.3 million reads to detect SNPs in the
genomic region of interest.
Data analysis
MiSeq reads were mapped to the HG38 reference genomewith bowtie 2.E4
SNP calls were made with Samtools Mpileup and BCFtools.E5 Annotation of
rs numbers was performed with an in-house custom script and data from
dbSNP for the targeted region. SNP function was determined with snpEff
and the Gencode V24 annotation.E6 The data from this study are available
in the NCBI BioProject database (ID: 315777).
Database screen for L285P prevalence
A comprehensive genetic database comprisingmore than 2000 Vietnamese
individuals genotyped with the Illumina Human Exome arrayE7,E8 was
screened but did not reveal the CD1a 285L location to be polymorphic. Further
examination of exome-sequenced East Asian samples,E9 as well as the 1000
Genomes project Phase 3 cosmopolitan database,E10 also did not reveal any
polymorphisms in the CD1 285L genomic location.
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Generation of L285P mutant and expression in HEK
and K562 cells
Construction of a BCMGSneo CD1a-expressing plasmid has been
described elsewhere.E11 To introduce the L285P mutant, an
overlap PCR was performed using primer pair CD1a_XhoI_FOR
59-CTTCTCGAGATGCTGTTTTTGCTACTTCC-39 and CD1a_mut_REV
59-ATGTCCTGGCCCTCTGGACTGCTGTGCTTCAC-39 and primer pair
CD1a_NotI_REV 59-CCACAGCGGCCGCTTAACAGAAACAGCGTTTC-
39 and CD1a_mut_FOR 59-TGAAGCACAGCAGTCCAGAGGGCCAGGA
CATC-39. Products were purified, mixed, and used as a template for an overlap
PCR using primer pair CD1a_XhoI_FOR and CD1a_NotI_REV. The final
product was digested with XhoI and NotI and subsequently ligated into the
parental vector.
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FIG E1. CD1a deficiency is generic and not confined to primary skin APCs. A,moDCs from a healthy control
donor and from donor 007 were stained either on the surface or intracellularly (i.c.) with anti-CD1a and
analyzed by flow cytometry. B, Immunohistochemistry of moDCs stained with anti-CD1a (green), anti-
EEA, an early endosome marker (red), and Hoechst (blue). Healthy control data are representative of 2 in-
dividuals. EEA, Early endosome antigen; FSC-A, Forward scatter-area; SSC-A, side scatter-area.
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FIG E2. Absence of surface CD1a detection in donor 007 is independent of the antibody clone used.
Monocyte-derived DCs from donors 003 and 007 were stained with anti-human CD1a clone OKT6. A positive
signal was observed only for donor 003. FSC-A, Forward scatter-area; SSC-A, side scatter-area.
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FIG E3. CD1a L285P is transcribed but not expressed as a protein on the cell surface.A,mRNA expression of
HEK and K562 cells-transfectedWT andmutant forms of CD1a. B, Detection of WT andmutant CD1a by anti-
CD1a clone NA1/34-HLK. HEK and K562 cells were transfected for 72 hours before analyzing the surface
expression of CD1a by flow cytometry. The expression pattern is similar to the one detected by anti-
CD1a clone HI149 (Fig 2). HEK, Human embryonic kidney; SSC-A, side scatter-area; WT, wild-type.
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FIG E4. CD1a deficiency is selective and spares CD1c and CD1d expression. CD1a expression on moDCs
from affected individuals and familymembers analyzed by flow cytometry (A) and immunofluorescencemi-
croscopy (B). C, Frequency of peripheral blood myeloid DC subsets, pDCs, and CD341 stem cells in the
affected family (black symbols) and healthy controls (open symbols). D, Frequency of total B cells and naive
B cells (CD191IgD1) in 007 family members and control donors. CD1c (E) and CD1d expression (F) on blood
DCs from 007 family members and control donors. Representative histograms for 007 and 1 control donor
are shown. Donor 007 (with the CD1a defect) is indicated in red. Cells from donor 005 were not available for
this analysis. MFI, Median fluorescence intensity; ns, nonsignificant.
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FIG E5. Sequence analysis of CD1a mRNA and gDNA identifies a novel mutation causing CD1a deficiency.
A, mRNA length of the CD1a ORF amplified from mRNA extracted from moDCs generated from 4 family
members. B, A thymidine (T) to cytidine (C) mutation identified bymRNA sequencing of donor 007 and fam-
ily members is indicated with a red box. C, Sequences of the genomic DNA (gDNA) of family members; the
CD1a gene position coding for the mutated mRNA is indicated with a red box. D, CD1a genotype tree of the
familymembers. The familymembers with CD1a deficiency are indicated in red. gDNA, Genomic DNA;ORF,
Open Reading Frame.
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TABLE E1. Summary clinical and laboratory information for the index case (007) and his immediate family
Subject 001 002 003 004 005 006 007—index case*
CD1a status rs538916791: C/C
rs761269454: T/C
Normal CD1a
rs538916791: C/A
rs761269454: T/T
Normal CD1a
rs538916791: C/A
rs761269454: T/T
Normal CD1a
rs538916791: C/A
rs761269454: T/T
Normal CD1a
rs538916791: C/A
rs761269454: T/C
CD1a deficiency
rs538916791: C/C
rs761269454: T/C
Normal CD1a
rs538916791: C/A
rs761269454: T/C
CD1a deficiency
Sex Female Male Male Male Male Male Male
Year of birth 1959 1956 1991 1982 1986 1985 1989
Occupation Farmer Farmer Businessman Businessman Construction worker Computer repair
business
Medical doctor
History (general) Arthritis,
hypertension,
vertigo
Parkinson’s disease,
anal fistula
Unremarkable Dengue, allergic
rhinitis
Gastritis, sinusitis,
Bell’s palsy
Labyrinthitis Complex forearm
fracture, internal
fixation
Skin abscesses or
recurrent skin
infections?
Occasional, in
childhood only
Occasional, in
childhood only
No No Moderate frequency,
in childhood only
Moderate frequency,
in childhood only
Moderate frequency,
in childhood only
Other skin
disorders
Mild acne
in the past
Moderate acne
in the past
Mild acne
(ongoing)
Mild acne and an
episode of herpes
zoster in the past
Mild acne and
folliculitis
(ongoing)
Moderate acne
(ongoing)
Minor fungal skin
infections and
warts
Mild acne and fungal
skin infections in
the past
Wound healing Normal, a few days Normal, a few days Normal, a few days Normal, a few days Normal, a few days Normal, a few days Normal, a few days
Reactions to bee
stings
No specific event
recalled
No specific event
recalled
1-2 events, mild
reactions
1-2 events, mild
reactions
>10 events, some
multiple; mild
reactions
>20 events, some
multiple;
moderate
reactions
1-2 events, mild
reactions
Reactions to wasp
stings
No stings No stings No stings 1-2 events, moderate
reactions
Once, moderate
reaction
1-2 events, moderate
reactions
No stings
Examination findings
General
examination
Unremarkable Parkinsonian Unremarkable Unremarkable Unremarkable Unremarkable Unremarkable
BMI 24.6 20.8 20.3 21.5 21.8 19.6 20.3
Visible BCG scar No No Yes, normal
appearance
No No No Yes, normal
appearance
Mantoux (5IU
PPD-S)
Not done Not done 9-mm response Not done 3-mm response Not done 10-mm response
Laboratory results
White blood cells 6.57 9.12 4.76 5.31 5.6 4.47 10.2
Hemoglobin 14 15.8 17.3 16 15.9 16.7 17
Platelets 222 241 161 174 227 127 216
Glucose 4.2 4.4 5.1 5.1 4.8 4.8 5.6
Creatinine 74 85 75 80 94 95 76
AST 31 22 16 18 23 26 20
ALT 21 11 18 28 19 38 40
GGT 8 31 23 23 24 29 26
Cholesterol 4.4 5.1 4.4 4.8 4.2 4.4 4.7
HDL 0.9 1.2 1.3 1.2 0.8/0.9 1.3 1.3
LDL 2.8 3.4 2.9 3.4 2.9 2.8 3.2
Triglyceride 1.7 1 1.4 1.5 2.5/2.6 1.1 1.3/1.6
Local normal ranges for hematology and biochemistry tests (abnormal results indicated in boldface):
White blood cells: Male/female: 6-10 K/mL.
Hemoglobin: 14.5-15.7 g/dL for men and 13-14 g/dL for women.
Platelets: 201-324 K/ml for men and 211-337 K/ml for women.
Glucose: 3.9-6.4 mmol/L.
Creatinine: 62-120 mmol/L for men and 53-100 mmol/L for women.
AST (aspartate aminotransferase): 0-40 U/L for men and 0-37 U/L for women.
ALT (alanine aminotransferase): 0-40 U/L for men and 0-33 U/L for women.
GGT (gamma glutamyl transferase): 11-50 U/L for men and 7-32 U/L for women.
Cholesterol: 3.9-5.2 mmol/L.
HDL (high density lipoprotein): 0.9-1.78 mmol/L.
LDL (low density lipoprotein): 1.15-3.4 mmol/L.
Triglyceride: 0.46-1.6 mmol/L for men and 0.68-1.88 mmol/L for women.
*Additional investigations were performed on the index case (007): electrolytes and plasma protein levels, bone biochemistry, thyroid function tests, immunoglobulin A, M, & G
levels, and an abdominal ultrasound were all normal.
BCG vaccination status uncertain—only subjects 003, 005, and 007 are thought to have received any vaccinations in infancy, but there are no records of what they were given.
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TABLE E2. SNP calls for the 13,807 base pairs sequenced in this study
SNP ID
Ref
name Position snpEff call
Reference
base
Alternative
base
Donor
001
001_
refC
001_
altC
001_
totC
Donor
002
002_
refC
002_
altC
002_
totC
Donor
003
rs75981383 chr1 158249693 Upstream modifier C G Het 39.20% 40.76% 2495 Het
rs3181029 chr1 158250175 Upstream modifier C T Het 40.09% 43.90% 4647 Het
rs3181031 chr1 158250679 Upstream modifier T C Het 42.39% 40.72% 2699
rs858998 chr1 158250785 Upstream modifier C T Hom 0.32% 84.07% 5890 Het
rs858999 chr1 158251080 Upstream modifier T C Hom 0.10% 81.32% 4165 Hom 0.06% 82.27% 1630 Hom
rs76519430 chr1 158251927 Upstream modifier G C Het 40.53% 39.52% 5428
rs79039536 chr1 158252071 Upstream modifier C T Het 44.44% 42.70% 2403
rs3136533 chr1 158253270 Upstream modifier G A Het 41.94% 45.31% 1867
rs6660005 chr1 158253691 Upstream modifier A G Het 47.37% 43.84% 1104
rs16840041 chr1 158254269 59 UTR modifier G A Het 46.42% 41.42% 3141
rs366316 chr1 158254492 59 UTR modifier A G Het 34.42% 45.92% 3190 Het
rs411089 chr1 158255035 Intron modifier C T Hom 0.49% 85.74% 4052 Het
rs2269714 chr1 158255114 Moderate missense:
aCc/aTc: T30I
C T Het 45.21% 44.37% 3942
rs2269715 chr1 158255229 Moderate missense:
tgC/tgG: C68W
C G Het 42.30% 39.36% 3402
rs538916791 chr1 158255306 Stop gained, high
nonsense: tCa/
tAa: S94*
C A Het 44.79% 41.29% 1969 Het
rs2269716 chr1 158255453 Intron modifier A T Het 39.99% 44.55% 2258
rs440419 chr1 158255606 Intron modifier G T Hom 0.10% 92.55% 3960 Het
rs2269717 chr1 158255730 Intron modifier T C Het 42.37% 47.33% 5863
rs11264948 chr1 158256617 Intron modifier C A Het 40.62% 36.45% 4867 Het
rs761269454 chr1 158257035 Moderate missense:
cTa/cCa: L285P
T C Het 38.79% 42.01% 7350
rs389293 chr1 158258602 Downstream
modifier
G A Het 44.28% 38.71% 2604 Het
rs550983993 chr1 158259566 Downstream
modifier
A T Het 45.89% 41.32% 1970
rs76706813 chr1 158260035 Downstream
modifier
G A Het 44.75% 43.31% 4177 Het
Note that ;20% of the reads were of low quality and not included in the SNP calls after mapping. SNPs in boldface are discussed in the text.
altC, Alternative base; _altC, percent of total reads with alternative base; het, heterogeneous; homo, homogeneous; refC, reference base; _refC, percent of total reads with reference
base, totC, total number of reads spanning the position.
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003_
refC
003_
altC
003_
totC
Donor
004
004_
refC
004_
altC
004_
totC
Donor
005
005_
refC
005_
altC
005_
totC
Donor
006
006_
refC
006_
altC
006_
totC
Donor
007
007_
refC
007_
altC
007_
totC
41.68% 39.89% 3397 Het 41.65% 40.11% 3712 Het 41.14% 37.41% 2144 Het 39.30% 37.89% 3112
42.31% 40.94% 6209 Het 41.97% 42.46% 6562 Het 40.23% 41.98% 3435 Het 38.85% 43.37% 5382
Het 39.08% 42.18% 2257
41.59% 43.19% 3200 Het 42.90% 41.55% 3427 Het 39.49% 42.36% 1636 Het 41.55% 40.98% 2084 Het 44.08% 38.42% 2829
0.19% 82.93% 2126 Hom 0.05% 83.99% 2130 Hom 0.19% 80.97% 1035 Hom 0.07% 79.49% 1487 Hom 0.09% 82.01% 2196
Het 40.46% 38.47% 5045
Het 47.66% 41.08% 2157
Het 41.07% 44.45% 1388
Het 54.90% 33.48% 938
Het 45.00% 37.76% 2031
36.82% 43.47% 4150 Het 37.44% 41.71% 4725 Het 33.22% 42.75% 3064 Het 30.40% 46.16% 2803
38.85% 47.87% 4903 Het 40.27% 45.80% 5419 Het 36.44% 48.09% 3271 Het 40.37% 45.65% 2668 Het 34.64% 50.41% 3271
Het 43.04% 47.49% 3325
Het 38.29% 38.79% 3643
42.17% 42.41% 2511 Het 42.91% 40.50% 2736 Het 39.91% 43.04% 1601 Het 39.86% 44.05% 1814
Het 42.27% 40.15% 2730
41.70% 47.23% 5461 Het 41.89% 47.31% 5842 Het 41.77% 44.78% 3546 Het 41.03% 45.06% 5062 Het 40.94% 45.41% 4279
Het 43.53% 43.87% 7574
38.59% 38.09% 7165 Het 38.79% 36.77% 6992 Het 40.59% 36.08% 3930 Het 38.54% 37.67% 4715
Het 37.10% 42.54% 5251 Het 38.03% 42.34% 7111 Het 38.80% 40.59% 5943
41.72% 41.53% 4293 Het 42.66% 41.76% 4440 Het 39.16% 38.65% 2533
Het 44.19% 41.66% 2331
44.43% 43.77% 6815 Het 44.31% 42.80% 7260 Het 43.43% 41.75% 4156
TABLE E2. (Continued)
J ALLERGY CLIN IMMUNOL
DECEMBER 2016
1712.e10 LETTERS TO THE EDITOR
TABLE E3. Primer sequences for CD1a gene
Genomic coordinates Target Forward Reverse Amplicon size
Overlap with
next amplicon
Chr 1: 158249137-158252175 Amplicon-1 atcaaacctaagctgactcctc accagacccatctcctctattg 3039 479
Chr 1: 158251697-158255283 Amplicon-2 aagtgttcctgcctttcttccag taatgtttccagttccttccac 3587 307
Chr 1: 158254976-158257976 Amplicon-3 atggatccccttttctccagattc ttaatagttgaacatgtggagg 3001 224
Chr 1: 158257752-158261027 Amplicon-4 ggctccagacacacctgaacac acaggtcaggtattcctaatgtg 3276 488
Chr 1: 158260539-158262943 Amplicon-5 aactgtatccaaagcctgaatg agtcgtcatttcaggttattgc 2404 NA
NA, Not applicable/available.
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